Omeros (NASDAQ:OMER) Receives Buy Rating from D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Omeros (NASDAQ:OMER) in a research report released on Tuesday,Benzinga reports. D. Boral Capital currently has a $36.00 target price on the biopharmaceutical company’s stock.

Several other equities research analysts have also commented on the stock. Needham & Company LLC restated a “hold” rating on shares of Omeros in a research report on Tuesday, April 1st. StockNews.com lowered shares of Omeros from a “hold” rating to a “sell” rating in a research report on Wednesday, April 9th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, two have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Omeros has a consensus rating of “Moderate Buy” and a consensus target price of $22.50.

Omeros Price Performance

NASDAQ:OMER opened at $4.43 on Tuesday. The firm’s fifty day moving average price is $7.28 and its 200 day moving average price is $8.15. Omeros has a 1-year low of $3.00 and a 1-year high of $13.60. The firm has a market cap of $258.30 million, a price-to-earnings ratio of -1.92 and a beta of 2.42.

Omeros (NASDAQ:OMER) last issued its earnings results on Monday, March 31st. The biopharmaceutical company reported ($0.63) EPS for the quarter, topping the consensus estimate of ($0.71) by $0.08. During the same quarter in the previous year, the business earned ($0.15) EPS. As a group, analysts expect that Omeros will post -3.09 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Omeros

Several institutional investors and hedge funds have recently made changes to their positions in OMER. Barclays PLC raised its stake in Omeros by 121.3% in the 3rd quarter. Barclays PLC now owns 94,640 shares of the biopharmaceutical company’s stock valued at $376,000 after purchasing an additional 51,873 shares during the last quarter. Quantbot Technologies LP acquired a new position in Omeros in the 4th quarter valued at about $46,000. Cerity Partners LLC raised its stake in Omeros by 9.9% in the 4th quarter. Cerity Partners LLC now owns 28,989 shares of the biopharmaceutical company’s stock valued at $286,000 after purchasing an additional 2,600 shares during the last quarter. New York State Common Retirement Fund raised its stake in Omeros by 245.4% in the 4th quarter. New York State Common Retirement Fund now owns 17,313 shares of the biopharmaceutical company’s stock valued at $171,000 after purchasing an additional 12,300 shares during the last quarter. Finally, Franklin Resources Inc. acquired a new position in Omeros in the 4th quarter valued at about $130,000. 48.79% of the stock is currently owned by hedge funds and other institutional investors.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.